表紙：ファーマコビジランスの世界市場 - 成長、将来展望、競合分析（2022年～2030年）

市場調査レポート

商品コード

1180743

ファーマコビジランスの世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Pharmacovigilance Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

出版日: 2022年08月24日 | 発行: Acute Market Reports

| ページ情報: 英文 115 Pages | 納期: 即日から翌営業日

価格

PDF (Single User License)

USD 4,500 707,130円

レポートPDFを1名のみがご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Multi User License)

USD 6,500 1,021,410円

レポートPDFを10名までご利用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

PDF (Enterprise License)

USD 9,000 1,414,260円

レポートPDFを企業内すべての方にご使用頂けるライセンスです。PDF内のテキスト等のコピー＆ペースト可能です。PDFの印刷は何回でも可能ですが、印刷したもののご利用はPDFのご利用範囲に準拠します。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

世界のファーマコビジランスの市場規模は、2022年から2030年の予測期間中に13.5%のCAGRで成長すると予測されています。副作用の事例の急増や慢性疾患（糖尿病、がんなど）の発生の増加は、薬剤消費の増加につながり、ファーマコビジランス市場の成長を促進する主な原動力の一部になっています。

当レポートでは、世界のファーマコビジランス市場について調査し、市場動向、競合情報、セグメント分析、新興動向、技術分析、企業プロファイルなどの情報を提供しています。

市場スナップショット：世界のファーマコビジランス市場
世界のファーマコビジランス市場：臨床試験フェーズ別（2021年）
世界のファーマコビジランス市場：メソッドタイプ別（2021年）
世界のファーマコビジランス市場：エンドユーザータイプ別（2021年）
世界のファーマコビジランス市場：サービスプロバイダータイプ別（2021年）
世界のファーマコビジランス市場：治療分野別（2021年）
世界のファーマコビジランス市場：地域別（2021年）
魅力的な投資提案：地域別（2021年）

第3章ファーマコビジランス市場：競合分析

主要なファーマコビジランス市場ベンダーの市場ポジショニング
ファーマコビジランス市場ベンダーの採用戦略
主要な業界戦略
階層分析：2021年対2030年

第4章ファーマコビジランス市場：マクロ分析と市場力学

イントロダクション
世界のファーマコビジランス市場金額（2020年～2030年）
市場力学
- 市場促進要因
- 市場抑制要因
- 主な課題
- 主な機会
促進要因と抑制要因の影響分析
シーソー分析

第5章ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）

市場概要
成長と収益分析：2021年対2030年
市場セグメンテーション
- 前臨床動物毒性
- 臨床試験フェーズI
- 臨床試験フェーズII
- 臨床試験フェーズIII
- 市販後調査

第6章ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）

市場概要
成長と収益分析：2021年対2030年
市場セグメンテーション
- 自発的報告
- 強化型副作用報告
- 標的型報告
- コホートイベントモニタリング
- EHRモニタリング

第7章ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）

市場概要
成長と収益分析：2021年対2030年
市場セグメンテーション
- 社内
- 契約アウトソーシング

第8章ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）

市場概要
成長と収益分析：2021年対2030年
市場セグメンテーション
- 病院
- 製薬企業
- その他

第9章ファーマコビジランス市場：治療分野別（2020年～2030年）

市場概要
成長と収益分析：2021年対2030年
市場セグメンテーション
- 腫瘍学
- 心臓病学
- 呼吸器系
- その他

第10章北米のファーマコビジランス市場（2020年～2030年）

市場概要
ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）
ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）
ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）
ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）
ファーマコビジランス市場：治療分野別（2020年～2030年）
ファーマコビジランス市場：地域別（2020年～2030年）
- 北米

第11章英国・欧州連合のファーマコビジランス市場（2020年～2030年）

市場概要
ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）
ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）
ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）
ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）
ファーマコビジランス市場：治療分野別（2020年～2030年）
ファーマコビジランス市場：地域別（2020年～2030年）
- 英国・欧州連合

第12章アジア太平洋のファーマコビジランス市場（2020年～2030年）

市場概要
ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）
ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）
ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）
ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）
ファーマコビジランス市場：治療分野別（2020年～2030年）
ファーマコビジランス市場：地域別（2020年～2030年）
- アジア太平洋

第13章ラテンアメリカのファーマコビジランス市場（2020年～2030年）

市場概要
ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）
ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）
ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）
ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）
ファーマコビジランス市場：治療分野別（2020年～2030年）
ファーマコビジランス市場：地域別（2020年～2030年）
- ラテンアメリカ

第14章中東・アフリカのファーマコビジランス市場（2020年～2030年）

市場概要
ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）
ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）
ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）
ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）
ファーマコビジランス市場：治療分野別（2020年～2030年）
ファーマコビジランス市場：地域別（2020年～2030年）
- 中東・アフリカ

第15章企業プロファイル

Accenture
BoehringerIngelheim
Bristol-Myers Squibb
Clinquest Group B.V.
Cognizant Technology Solutions Corporation
EcronAcunova Ltd.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline
HCL Technologies
IBM Corporation

図表

List of Tables

TABLE 1 Global Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 2 Global Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 3 Global Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 4 Global Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 5 Global Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 6 North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 7 North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 8 North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 9 North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 10 North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 11 U.S. Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 12 U.S. Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 13 U.S. Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 14 U.S. Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 15 U.S. Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 16 Canada Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 17 Canada Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 18 Canada Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 19 Canada Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 20 Canada Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 21 Rest of North America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 22 Rest of North America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 23 Rest of North America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 24 Rest of North America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 25 Rest of North America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 26 UK and European Union Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 27 UK and European Union Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 28 UK and European Union Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 29 UK and European Union Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 30 UK and European Union Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 31 UK Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 32 UK Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 33 UK Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 34 UK Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 35 UK Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 36 Germany Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 37 Germany Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 38 Germany Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 39 Germany Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 40 Germany Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 41 Spain Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 42 Spain Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 43 Spain Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 44 Spain Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 45 Spain Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 46 Italy Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 47 Italy Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 48 Italy Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 49 Italy Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 50 Italy Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 51 France Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 52 France Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 53 France Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 54 France Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 55 France Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 56 Rest of Europe Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 57 Rest of Europe Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 58 Rest of Europe Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 59 Rest of Europe Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 60 Rest of Europe Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 61 Asia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 62 Asia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 63 Asia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 64 Asia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 65 Asia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 66 China Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 67 China Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 68 China Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 69 China Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 70 China Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 71 Japan Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 72 Japan Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 73 Japan Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 74 Japan Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 75 Japan Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 76 India Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 77 India Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 78 India Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 79 India Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 80 India Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 81 Australia Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 82 Australia Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 83 Australia Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 84 Australia Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 85 Australia Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 86 South Korea Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 87 South Korea Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 88 South Korea Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 89 South Korea Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 90 South Korea Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 91 Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 92 Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 93 Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 94 Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 95 Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 96 Brazil Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 97 Brazil Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 98 Brazil Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 99 Brazil Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 100 Brazil Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 101 Mexico Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 102 Mexico Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 103 Mexico Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 104 Mexico Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 105 Mexico Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 106 Rest of Latin America Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 107 Rest of Latin America Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 108 Rest of Latin America Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 109 Rest of Latin America Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 110 Rest of Latin America Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 111 Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 112 Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 113 Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 114 Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 115 Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 116 GCC Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 117 GCC Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 118 GCC Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 119 GCC Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 120 GCC Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 121 Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 122 Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 123 Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 124 Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 125 Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)
TABLE 126 Rest of Middle East and Africa Pharmacovigilance Market By Clinical Trial Phase, 2020-2030, USD (Million)
TABLE 127 Rest of Middle East and Africa Pharmacovigilance Market By Type of Method, 2020-2030, USD (Million)
TABLE 128 Rest of Middle East and Africa Pharmacovigilance Market By Type of End User, 2020-2030, USD (Million)
TABLE 129 Rest of Middle East and Africa Pharmacovigilance Market By Type of Service Provider, 2020-2030, USD (Million)
TABLE 130 Rest of Middle East and Africa Pharmacovigilance Market By Therapeutic Area, 2020-2030, USD (Million)

List of Figures

FIG. 1 Global Pharmacovigilance Market: Market Coverage
FIG. 2 Research Methodology and Data Sources
FIG. 3 Market Size Estimation - Top Down & Bottom-Up Approach
FIG. 4 Global Pharmacovigilance Market: Quality Assurance
FIG. 5 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021
FIG. 6 Global Pharmacovigilance Market, By Type of Method, 2021
FIG. 7 Global Pharmacovigilance Market, By Type of End User, 2021
FIG. 8 Global Pharmacovigilance Market, By Type of Service Provider, 2021
FIG. 9 Global Pharmacovigilance Market, By Therapeutic Area, 2021
FIG. 10 Global Pharmacovigilance Market, By Geography, 2021
FIG. 11 Market Geographical Opportunity Matrix - Global Pharmacovigilance Market, 2021
FIG. 12 Market Positioning of Key Pharmacovigilance Market Players, 2021
FIG. 13 Global Pharmacovigilance Market - Tier Analysis - Percentage of Revenues by Tier Level, 2021 Versus 2030
FIG. 14 Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 Vs 2030, %
FIG. 15 Global Pharmacovigilance Market, By Type of Method, 2021 Vs 2030, %
FIG. 16 Global Pharmacovigilance Market, By Type of End User, 2021 Vs 2030, %
FIG. 17 Global Pharmacovigilance Market, By Type of Service Provider, 2021 Vs 2030, %
FIG. 18 Global Pharmacovigilance Market, By Therapeutic Area, 2021 Vs 2030, %
FIG. 19 U.S. Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 20 Canada Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 21 Rest of North America Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 22 UK Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 23 Germany Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 24 Spain Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 25 Italy Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 26 France Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 27 Rest of Europe Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 28 China Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 29 Japan Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 30 India Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 31 Australia Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 32 South Korea Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 33 Rest of Asia Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 34 Brazil Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 35 Mexico Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 36 Rest of Latin America Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 37 GCC Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 38 Africa Pharmacovigilance Market (US$ Million), 2020 - 2030
FIG. 39 Rest of Middle East and Africa Pharmacovigilance Market (US$ Million), 2020 - 2030

Product Code: 136781-08-22

The pharmacovigilance (phv) market is anticipated to grow at a compound annual growth rate of 13.5% for the forecasted period (2022 - 2030). As the world's population ages, chronic diseases have increased; and more adverse drug reactions mean more pharmacovigilance. Pharmacovigilance (drug safety) is the healthcare industry's effort to ensure that pharmaceutical companies' claims are accurate and supported by scientific evidence. This report covers all the quantitative and qualitative aspects of pharmacovigilance market and also talks about its key drivers, the challenges it faces, the growth opportunities present in the market, and its future prospects.

Post Marketing Surveillance Phase Takes the Largest Slice

The market has been segmented on basis of Clinical Trial Phases, Service Providers, End Users, Methods, and Regional Basis. On the basis of Clinical Trials, Phase IV i.e. Post Marketing Surveillance Phase has a presiding share of about 75.6% for the year 2020 whereas On the basis of Service Provider, Contract Outsourcing has a presiding share of about 59.2%. Spontaneous Reporting has a dominant share of 30.3% for the year 2020 because of its usefulness in detecting new, serious and rare adverse drug reaction cases and moreover it is an efficient and inexpensive method of reporting ADRs. After Spontaneous Reporting, Cohort Event Monitoring is expected to show growth exponentially over a forecast period. While viewing Phv Market on basis of therapeutic areas, oncology (The study and Treatment of Tumours) dominates the market with a share of about 26.5% whereas while viewing it on basis of end Users, pharmaceuticals dominates the market with a share of 42.6%.

Pharmacovigilance Market: Drivers and Challenges

The surge in cases of Adverse drug reaction (ADR), the increasing occurrence of Chronic Diseases (Diabetes, Cancer, etc.) which in turn lead to increased drug consumption are a few of the main underlying forces driving the growth of the Phv Market. 5% of hospitalizations in Europe and the U.S.in the year 2019 were due to adverse drug reaction cases. Iatrogenic disease is the most common disease caused due to adverse drug reactions.

According to a study by Tufts University, 40% of Adverse Drug Events are never reported by Healthcare Professionals. Another major problem in Spontaneous Reporting of Adverse drug events (ADE) is misreporting and miscoding of reports. The data mentioned in reports under the fields of dosage, formulation type, time, and length of exposure to ADE is not clearly stated.

Pharmacovigilance Market: Key Player and Market

For the year 2020, North America dominated the Pharmacovigilance Market with a fair share of about 34% due to the presence of key pharmaceuticals and MDMs (Medical Device Players) whereas the Asia Pacific is anticipated to have a compound annual growth rate of 13.5% attributable to its accessibility of various outsourcing organizations. Industry leaders are targeting on developing research and development activities, new product launches, collaborating with leading Pharmaceutical companies in order to spread awareness about proper use of medicines and having access to medical information.Few of the pharmacovigilance market's key players are- BoehringerIngelheim, Bristol-Myers Squibb, Clinquest Group B.V., EcronAcunova Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline, HCL Technologies, Accenture, Cognizant, IBM Corporation, Wipro Limited.

Historical & Forecast Period

This study report represents analysis of each segment from 2020 to 2030 considering 2021 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2022 to 2030.

The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.

Research Methodology

The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Pharmacovigilance market are as follows:

Research and development budgets of manufacturers and government spending

Revenues of key companies in the market segment

Number of end users and consumption volume, price and value.

Geographical revenues generate by countries considered in the report:

Micro and macro environment factors that are currently influencing the Pharmacovigilance market and their expected impact during the forecast period.

Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.

Market Market Segmentation

Clinical Trial Phase

Preclinical Animal Toxicity

Clinical Trial Phase I

Clinical Trial Phase II

Clinical Trial Phase III

Post Marketing Surveillance

Type of Method

Spontaneous Reporting

Intensified Adverse Drug Reaction Reporting

Targeted Reporting

Cohort Event Monitoring

EHR Monitoring

Type of End User

In-House

Contract Outsourcing

Type of Service Provider

Hospitals

Pharmaceutical Companies

Others

Therapeutic Area

Oncology

Cardiology

Respiratory Systems

Others

Region Segment (2020-2030; US$ Million)

North America

U.S.

Canada

Rest of North America

UK and European Union

Germany

Spain

Italy

France

Rest of Europe

Asia Pacific

China

Japan

India

Australia

South Korea

Rest of Asia Pacific

Latin America

Brazil

Mexico

Rest of Latin America

Middle East and Africa

GCC

Africa

Rest of Middle East and Africa

Global Impact of COVID-19 Segment (2020-2021; US$ Million )

Pre COVID-19 situation

Post COVID-19 situation

Key questions answered in this report:

What are the key micro and macro environmental factors that are impacting the growth of Pharmacovigilance market?

What are the key investment pockets with respect to product segments and geographies currently and during the forecast period?

Estimated forecast and market projections up to 2030.

Which segment accounts for the fastest CAGR during the forecast period?

Which market segment holds a larger market share and why?

Are low and middle-income economies investing in the Pharmacovigilance market?

Which is the largest regional market for Pharmacovigilance market?

What are the market trends and dynamics in emerging markets such as Asia Pacific, Latin America, and Middle East & Africa?

Which are the key trends driving Pharmacovigilance market growth?

Who are the key competitors and what are their key strategies to enhance their market presence in the Pharmacovigilance market worldwide?

1. Preface

1.1. Report Description
- 1.1.1. Purpose of the Report
- 1.1.2. Target Audience
- 1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
- 1.3.1. Phase I - Secondary Research
- 1.3.2. Phase II - Primary Research
- 1.3.3. Phase III - Expert Panel Review
- 1.3.4. Assumptions
- 1.3.5. Approach Adopted

2. Executive Summary

2.1. Market Snapshot: Global Pharmacovigilance Market
2.2. Global Pharmacovigilance Market, By Clinical Trial Phase, 2021 (US$ Million)
2.3. Global Pharmacovigilance Market, By Type of Method, 2021 (US$ Million)
2.4. Global Pharmacovigilance Market, By Type of End User, 2021 (US$ Million)
2.5. Global Pharmacovigilance Market, By Type of Service Provider, 2021 (US$ Million)
2.6. Global Pharmacovigilance Market, By Therapeutic Area, 2021 (US$ Million)
2.7. Global Pharmacovigilance Market, By Geography, 2021 (US$ Million)
2.8. Attractive Investment Proposition by Geography, 2021

3. Pharmacovigilance Market: Competitive Analysis

3.1. Market Positioning of Key Pharmacovigilance Market Vendors
3.2. Strategies Adopted by Pharmacovigilance Market Vendors
3.3. Key Industry Strategies
3.4. Tier Analysis 2021 Versus 2030

4. Pharmacovigilance Market: Macro Analysis & Market Dynamics

4.1. Introduction
4.2. Global Pharmacovigilance Market Value, 2020 - 2030, (US$ Million)
4.3. Market Dynamics
- 4.3.1. Market Drivers
- 4.3.2. Market Restraints
- 4.3.3. Key Challenges
- 4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis

5. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)

5.1. Market Overview
5.2. Growth & Revenue Analysis: 2021 Versus 2030
5.3. Market Segmentation
- 5.3.1. Preclinical Animal Toxicity
- 5.3.2. Clinical Trial Phase I
- 5.3.3. Clinical Trial Phase II
- 5.3.4. Clinical Trial Phase III
- 5.3.5. Post Marketing Surveillance

6. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)

6.1. Market Overview
6.2. Growth & Revenue Analysis: 2021 Versus 2030
6.3. Market Segmentation
- 6.3.1. Spontaneous Reporting
- 6.3.2. Intensified Adverse Drug Reaction Reporting
- 6.3.3. Targeted Reporting
- 6.3.4. Cohort Event Monitoring
- 6.3.5. EHR Monitoring

7. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)

7.1. Market Overview
7.2. Growth & Revenue Analysis: 2021 Versus 2030
7.3. Market Segmentation
- 7.3.1. In-House
- 7.3.2. Contract Outsourcing

8. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)

8.1. Market Overview
8.2. Growth & Revenue Analysis: 2021 Versus 2030
8.3. Market Segmentation
- 8.3.1. Hospitals
- 8.3.2. Pharmaceutical Companies
- 8.3.3. Others

9. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

9.1. Market Overview
9.2. Growth & Revenue Analysis: 2021 Versus 2030
9.3. Market Segmentation
- 9.3.1. Oncology
- 9.3.2. Cardiology
- 9.3.3. Respiratory Systems
- 9.3.4. Others

10. North America Pharmacovigilance Market, 2020-2030, USD (Million)

10.1. Market Overview
10.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
10.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
10.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
10.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
10.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
10.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
- 10.7.1.North America
  - 10.7.1.1. U.S.
    - 10.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 10.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 10.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 10.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 10.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 10.7.1.2. Canada
    - 10.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 10.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 10.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 10.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 10.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 10.7.1.3. Rest of North America
    - 10.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 10.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 10.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 10.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 10.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

11. UK and European Union Pharmacovigilance Market, 2020-2030, USD (Million)

11.1. Market Overview
11.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
11.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
11.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
11.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
11.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
11.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
- 11.7.1.UK and European Union
  - 11.7.1.1. UK
    - 11.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 11.7.1.2. Germany
    - 11.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 11.7.1.3. Spain
    - 11.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 11.7.1.4. Italy
    - 11.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.4.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.4.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.4.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.4.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 11.7.1.5. France
    - 11.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.5.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.5.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.5.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.5.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 11.7.1.6. Rest of Europe
    - 11.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 11.7.1.6.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 11.7.1.6.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 11.7.1.6.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 11.7.1.6.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

12. Asia Pacific Pharmacovigilance Market, 2020-2030, USD (Million)

12.1. Market Overview
12.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
12.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
12.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
12.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
12.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
12.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
- 12.7.1.Asia Pacific
  - 12.7.1.1. China
    - 12.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 12.7.1.2. Japan
    - 12.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 12.7.1.3. India
    - 12.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 12.7.1.4. Australia
    - 12.7.1.4.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.4.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.4.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.4.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.4.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 12.7.1.5. South Korea
    - 12.7.1.5.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.5.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.5.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.5.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.5.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 12.7.1.6. Rest of Asia Pacific
    - 12.7.1.6.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 12.7.1.6.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 12.7.1.6.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 12.7.1.6.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 12.7.1.6.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

13. Latin America Pharmacovigilance Market, 2020-2030, USD (Million)

13.1. Market Overview
13.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
13.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
13.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
13.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
13.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
13.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
- 13.7.1.Latin America
  - 13.7.1.1. Brazil
    - 13.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 13.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 13.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 13.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 13.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 13.7.1.2. Mexico
    - 13.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 13.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 13.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 13.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 13.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 13.7.1.3. Rest of Latin America
    - 13.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 13.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 13.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 13.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 13.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

14. Middle East and Africa Pharmacovigilance Market, 2020-2030, USD (Million)

14.1. Market Overview
14.2. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
14.3. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
14.4. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
14.5. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
14.6. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
14.7.Pharmacovigilance Market: By Region, 2020-2030, USD (Million)
- 14.7.1.Middle East and Africa
  - 14.7.1.1. GCC
    - 14.7.1.1.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 14.7.1.1.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 14.7.1.1.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 14.7.1.1.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 14.7.1.1.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 14.7.1.2. Africa
    - 14.7.1.2.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 14.7.1.2.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 14.7.1.2.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 14.7.1.2.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 14.7.1.2.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)
  - 14.7.1.3. Rest of Middle East and Africa
    - 14.7.1.3.1. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)
    - 14.7.1.3.1. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)
    - 14.7.1.3.1. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)
    - 14.7.1.3.1. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)
    - 14.7.1.3.1. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

15. Company Profile

15.1. Accenture
- 15.1.1. Company Overview
- 15.1.2. Financial Performance
- 15.1.3. Product Portfolio
- 15.1.4. Strategic Initiatives
15.2. BoehringerIngelheim
- 15.2.1. Company Overview
- 15.2.2. Financial Performance
- 15.2.3. Product Portfolio
- 15.2.4. Strategic Initiatives
15.3. Bristol-Myers Squibb
- 15.3.1. Company Overview
- 15.3.2. Financial Performance
- 15.3.3. Product Portfolio
- 15.3.4. Strategic Initiatives
15.4. Clinquest Group B.V.
- 15.4.1. Company Overview
- 15.4.2. Financial Performance
- 15.4.3. Product Portfolio
- 15.4.4. Strategic Initiatives
15.5. Cognizant Technology Solutions Corporation
- 15.5.1. Company Overview
- 15.5.2. Financial Performance
- 15.5.3. Product Portfolio
- 15.5.4. Strategic Initiatives
15.6. EcronAcunova Ltd.
- 15.6.1. Company Overview
- 15.6.2. Financial Performance
- 15.6.3. Product Portfolio
- 15.6.4. Strategic Initiatives
15.7. F. Hoffmann-La Roche Ltd.
- 15.7.1. Company Overview
- 15.7.2. Financial Performance
- 15.7.3. Product Portfolio
- 15.7.4. Strategic Initiatives
15.8. GlaxoSmithKline
- 15.8.1. Company Overview
- 15.8.2. Financial Performance
- 15.8.3. Product Portfolio
- 15.8.4. Strategic Initiatives
15.9. HCL Technologies
- 15.9.1. Company Overview
- 15.9.2. Financial Performance
- 15.9.3. Product Portfolio
- 15.9.4. Strategic Initiatives
15.10. IBM Corporation
- 15.10.1. Company Overview
- 15.10.2. Financial Performance
- 15.10.3. Product Portfolio
- 15.10.4. Strategic Initiatives

ファーマコビジランスの世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Pharmacovigilance Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章序文

第2章エグゼクティブサマリー

第3章ファーマコビジランス市場：競合分析

第4章ファーマコビジランス市場：マクロ分析と市場力学

第5章ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）

第6章ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）

第7章ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）

第8章ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）

第9章ファーマコビジランス市場：治療分野別（2020年～2030年）

第10章北米のファーマコビジランス市場（2020年～2030年）

第11章英国・欧州連合のファーマコビジランス市場（2020年～2030年）

第12章アジア太平洋のファーマコビジランス市場（2020年～2030年）

第13章ラテンアメリカのファーマコビジランス市場（2020年～2030年）

第14章中東・アフリカのファーマコビジランス市場（2020年～2030年）

第15章企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. Pharmacovigilance Market: Competitive Analysis

4. Pharmacovigilance Market: Macro Analysis & Market Dynamics

5. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)

6. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)

7. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)

8. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)

9. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

10. North America Pharmacovigilance Market, 2020-2030, USD (Million)

11. UK and European Union Pharmacovigilance Market, 2020-2030, USD (Million)

12. Asia Pacific Pharmacovigilance Market, 2020-2030, USD (Million)

13. Latin America Pharmacovigilance Market, 2020-2030, USD (Million)

14. Middle East and Africa Pharmacovigilance Market, 2020-2030, USD (Million)

15. Company Profile

ファーマコビジランスの世界市場 - 成長、将来展望、競合分析（2022年～2030年）

Pharmacovigilance Market - Growth, Future Prospects and Competitive Analysis, 2022 - 2030

目次

第1章 序文

第2章 エグゼクティブサマリー

第3章 ファーマコビジランス市場：競合分析

第4章 ファーマコビジランス市場：マクロ分析と市場力学

第5章 ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）

第6章 ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）

第7章 ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）

第8章 ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）

第9章 ファーマコビジランス市場：治療分野別（2020年～2030年）

第10章 北米のファーマコビジランス市場（2020年～2030年）

第11章 英国・欧州連合のファーマコビジランス市場（2020年～2030年）

第12章 アジア太平洋のファーマコビジランス市場（2020年～2030年）

第13章 ラテンアメリカのファーマコビジランス市場（2020年～2030年）

第14章 中東・アフリカのファーマコビジランス市場（2020年～2030年）

第15章 企業プロファイル

List of Tables

List of Figures

Table of Contents

1. Preface

2. Executive Summary

3. Pharmacovigilance Market: Competitive Analysis

4. Pharmacovigilance Market: Macro Analysis & Market Dynamics

5. Pharmacovigilance Market: By Clinical Trial Phase, 2020-2030, USD (Million)

6. Pharmacovigilance Market: By Type of Method, 2020-2030, USD (Million)

7. Pharmacovigilance Market: By Type of End User, 2020-2030, USD (Million)

8. Pharmacovigilance Market: By Type of Service Provider, 2020-2030, USD (Million)

9. Pharmacovigilance Market: By Therapeutic Area, 2020-2030, USD (Million)

10. North America Pharmacovigilance Market, 2020-2030, USD (Million)

11. UK and European Union Pharmacovigilance Market, 2020-2030, USD (Million)

12. Asia Pacific Pharmacovigilance Market, 2020-2030, USD (Million)

13. Latin America Pharmacovigilance Market, 2020-2030, USD (Million)

14. Middle East and Africa Pharmacovigilance Market, 2020-2030, USD (Million)

15. Company Profile

第1章序文

第2章エグゼクティブサマリー

第3章ファーマコビジランス市場：競合分析

第4章ファーマコビジランス市場：マクロ分析と市場力学

第5章ファーマコビジランス市場：臨床試験フェーズ別（2020年～2030年）

第6章ファーマコビジランス市場：メソッドタイプ別（2020年～2030年）

第7章ファーマコビジランス市場：エンドユーザータイプ別（2020年～2030年）

第8章ファーマコビジランス市場：サービスプロバイダータイプ別（2020年～2030年）

第9章ファーマコビジランス市場：治療分野別（2020年～2030年）

第10章北米のファーマコビジランス市場（2020年～2030年）

第11章英国・欧州連合のファーマコビジランス市場（2020年～2030年）

第12章アジア太平洋のファーマコビジランス市場（2020年～2030年）

第13章ラテンアメリカのファーマコビジランス市場（2020年～2030年）

第14章中東・アフリカのファーマコビジランス市場（2020年～2030年）

第15章企業プロファイル